Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The Global Fund has announced that it signed an access agreement with Gilead Sciences to procure lenacapavir, a twice-a-year injection that has a 99 per cent success rate in preventing HIV ...